SYNI Stock Overview
A product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Synvista Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | 9,900.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| SYNI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.6% |
| 1Y | n/a | 14.2% | 32.3% |
Return vs Industry: Insufficient data to determine how SYNI performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SYNI performed against the US Market.
Price Volatility
| SYNI volatility | |
|---|---|
| SYNI Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SYNI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SYNI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | n/a | n/a |
Synvista Therapeutics, Inc., a product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. The company’s products include ALT-2074, a glutathione peroxidase mimetic in Phase II clinical trials for the treatment of diabetic patients with Hp2-2; and Alagebrium chloride or alagebrium, an Advanced Glycation End-product Crosslink Breaker in Phase II clinical trials for the treatment of diastolic heart failure and diabetic nephropathy. It is also developing a diagnostic test to identify and treat patients with diabetes who are in risk of cardiovascular disease.
Synvista Therapeutics, Inc. Fundamentals Summary
| SYNI fundamental statistics | |
|---|---|
| Market cap | US$258.00 |
| Earnings (TTM) | -US$19.80m |
| Revenue (TTM) | US$54.73k |
0.0x
P/S Ratio0.0x
P/E RatioIs SYNI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYNI income statement (TTM) | |
|---|---|
| Revenue | US$54.73k |
| Cost of Revenue | US$0 |
| Gross Profit | US$54.73k |
| Other Expenses | US$19.86m |
| Earnings | -US$19.80m |
Last Reported Earnings
Sep 30, 2008
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did SYNI perform over the long term?
See historical performance and comparison